Compare BIO-TECHNE Corp (TECH) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Valero Energy Corporation — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Valero Energy Corporation trades at $391.21 (market cap $110.23B). The key difference: Valero Energy Corporation is far larger — about 9.7× BIO-TECHNE Corp's market cap, and Valero Energy Corporation pays the higher dividend (1.25%). Which is the better fit depends on your goals.
| TECH | VLO | |
|---|---|---|
Market Cap | $11.34B | $110.23B |
Sector | Health | Energy |
52-Week High | $72.48 | $388.95 |
52-Week Low | $43.31 | $156.39 |
Enterprise Value | $11.36B | $113.71B |
Dividend Yield | 0.44% | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Valero Energy (VLO) trades at $382.85, up 3.27% with strong technical momentum and bullish moving averages. The stock shows robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and attractive valuation ratios (P/E 15.97, P/S 0.83). Recent news highlights inclusion in growth stock lists and upcoming Q3 2026 earnings on October 22, 2026.
Outlook remains positive with favorable refining conditions and analyst consensus at Buy (58%). Key risks include revenue decline from $176.4B (2022) to $122.7B (2025) and political pressure on gas prices. The stock offers value but faces sector volatility and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
